Search Results - therapeutic+substance

251 Results

Sort By:

bio-IB3

Unmet NeedAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with time. Currently, the diagnosis of Alzheimer’s disease...

Published: 3/12/2026 | Inventor(s): Esther Oh, Stina Tucker, David Borchelt, Juan Troncoso

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Neurodegeneration, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration

L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the...

Published: 3/12/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

New Therapeutic Approach for the Treatment of Neuropathic Pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

A peptide that forms pores in membranes at acidic pH for the delivery of macromolecules through the plasma membrane or endosomes, or the lysis of cancer cells.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 3/12/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 3/12/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...

Published: 3/12/2026 | Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity

Value Proposition· Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4· The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...

Published: 3/12/2026 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Polymeric particles for sustained delivery of multimodal peptide therapeutics

Value Proposition· Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects· Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration· Flexible formulation approaches: system's...

Published: 3/12/2026 | Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski

Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 3/12/2026 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

1 2 3 4 5 6 7 8 9 10 ...